LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
Ascidian Therapeutics
United States
- Boston, MA
- 17/10/2022
- Series A
- $50,000,000
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs. For more information, visit www.ascidian-tx.com.
- Industry Biotechnology Research
- Website https://www.ascidian-tx.com/
- LinkedIn https://www.linkedin.com/company/ascidian-therapeutics/
Related People
Romesh SubramanianFounder
United States -
Cambridge, Massachusetts,
Company formation, deal sourcing, strategy development, financing and execution to provide patient benefit. Expertise in nucleic acid, antibody and peptide therapeutics targeting orphan and rare diseases, oncology, renal and metabolic disease indications. Extensive experience developing strategy and teams to progress programs through clinical development.
Specialties: R&D
Orphan and Rare Disease
Metabolic disease
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)